Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Shares Outstanding (Weighted Average) (2016 - 2025)

International Stem Cell (ISCO) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $8.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) changed 0.0% to $8.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.0 million, a 0.0% change, with the full-year FY2024 number at $8.0 million, changed 0.0% from a year prior.
  • Shares Outstanding (Weighted Average) was $8.0 million for Q3 2025 at International Stem Cell, roughly flat from $8.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $8.0 million in Q4 2022 to a low of $7.5 million in Q1 2021.
  • A 5-year average of $8.0 million and a median of $8.0 million in 2022 define the central range for Shares Outstanding (Weighted Average).
  • Biggest YoY gain for Shares Outstanding (Weighted Average) was 6.17% in 2021; the steepest drop was 0.0% in 2021.
  • International Stem Cell's Shares Outstanding (Weighted Average) stood at $7.8 million in 2021, then rose by 2.19% to $8.0 million in 2022, then changed by 0.0% to $8.0 million in 2023, then changed by 0.0% to $8.0 million in 2024, then changed by 0.0% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Shares Outstanding (Weighted Average) are $8.0 million (Q3 2025), $8.0 million (Q2 2025), and $8.0 million (Q1 2025).